Ikena Oncology Inc. (IKNA)
1.30
-0.04 (-2.99%)
At close: Mar 03, 2025, 12:42 PM
Company Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.
Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.
The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology Inc.
| Country | United States |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Dr. Mark Manfredi Ph.D. |
Contact Details
Address: 645 Summer Street Boston, Massachusetts United States | |
| Website | https://ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Financial Officer & Head of Corporate Development |
| Bob Lally | Senior Vice President of Finance & Operations |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 10, 2025 | 425 | Filing |
| Dec 31, 2024 | SCHEDULE 13G | Filing |
| Dec 23, 2024 | 425 | Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |